ReviewJournal of clinical medicine2018
Drug-Induced Interstitial Lung Disease: A Systematic Review.
Review in Journal of clinical medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 231 papers, 8 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
231 citing papers in PubMed, 8 syntheses or guidelines pooled it, 396 citations in OpenAlex.
- Analysis of interstitial lung disease in pharmacovigilance databases: Coding challenges and interpretation biases-An update.British journal of clinical pharmacology · 2026Pooled it
- Pooled it
- Pathogenic mechanisms and resistance profiles of microbial pulmonary infections in lung cancer: a systematic review.BMC infectious diseases · 2025Pooled it
- Interstitial lung disease in targeted therapies: A Society of Gynecologic Oncology clinical practice statement.Gynecologic oncology · 2025Guideline
- Interstitial lung disease epidemiology and etiology in patients with solid malignant tumors: a systematic literature review.Future oncology (London, England) · 2025Pooled it
- 6th and 7th International consensus guidelines for the management of advanced breast cancer (ABC guidelines 6 and 7).Breast (Edinburgh, Scotland) · 2024Guideline
- Incidence and prevalence of interstitial lung diseases worldwide: a systematic literature review.BMJ open respiratory research · 2023Pooled it
- A systematic review of the incidence, risk factors and prognosis of acute exacerbation of systemic autoimmune disease-associated interstitial lung disease.BMC pulmonary medicine · 2021Pooled it
- Trastuzumab deruxtecan versus trastuzumab emtansine in Asian patients with HER2-positive metastatic breast cancer.Cancer science · 2024Trial
- Efficacy and exploratory biomarker analysis of entinostat plus exemestane in advanced or recurrent breast cancer: phase II randomized controlled trial.Japanese journal of clinical oncology · 2023Trial
- Levofloxacin-Induced Eosinophilic Pneumonia with Systemic Manifestations: A Case Report and Literature Review.Internal medicine (Tokyo, Japan) · 2026Review
- Article
- Interstitial Lung Disease and Cardiotoxicity Associated with Trastuzumab Deruxtecan, Sacituzumab Govitecan, and Trastuzumab Emtansine: A Narrative Review.Medicina (Kaunas, Lithuania) · 2026Review
- Interstitial lung disease in metastatic breast cancer: a landscape review using SEER-Medicare.Breast cancer research and treatment · 2026Article
- Pathophysiological and Molecular Features of DXd ADC-Related Interstitial Pneumonitis in Cynomolgus Monkeys.Cancer science · 2026Article
- A Mimic of Metastatic Malignancy: Dietary Supplement-Associated Drug-Induced Lung Injury Presenting as Multiple Pulmonary Nodules With an Acute Fibrinous and Organizing Pneumonia Pattern.Respirology case reports · 2026Article
- Changes in the Quantitative Computed Tomography Values in Drug-associated Interstitial Lung Disease Caused by Non-anticancer Drugs.Internal medicine (Tokyo, Japan) · 2026Article
- Current perspectives on natural and pharmacological interventions for combating drug-induced pulmonary toxicity.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- Article
- Atomoxetine attenuates methotrexate-induced lung injury in rats implicating TLR4/NF-κB and Bax/Bcl-2/caspase-3 signaling cascades: a study based on molecular docking and experimental validation.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
171 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 7 institutions in 2 countries.
Funding
Abstract
backgroundDrug-induced interstitial lung disease (DIILD) occurs as a result of numerous agents, but the risk often only becomes apparent after the marketing authorisation of such agents.
methodsIn this PRISMA-compliant systematic review, we aimed to evaluate and synthesise the current literature on DIILD.
resultsFollowing a quality assessment, 156 full-text papers describing more than 6000 DIILD cases were included in the review. However, the majority of the papers were of low or very low quality in relation to the review question (78%). Thus, it was not possible to perform a meta-analysis, and descriptive review was undertaken instead. DIILD incidence rates varied between 4.1 and 12.4 cases/million/year. DIILD accounted for 3⁻5% of prevalent ILD cases. Cancer drugs, followed by rheumatology drugs, amiodarone and antibiotics, were the most common causes of DIILD. The radiopathological phenotype of DIILD varied between and within agents, and no typical radiological pattern specific to DIILD was identified. Mortality rates of over 50% were reported in some studies. Severity at presentation was the most reliable predictor of mortality. Glucocorticoids (GCs) were commonly used to treat DIILD, but no prospective studies examined their effect on outcome.
conclusionsOverall high-quality evidence in DIILD is lacking, and the current review will inform larger prospective studies to investigate the diagnosis and management of DIILD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.